Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pravastatin in diabetes-associated hypercholesterolemia

C Rustemeijer1, J A Schouten, E N Janssens

  • 1Ziekenhuis Amstelveen, The Netherlands.

Acta Diabetologica
|February 6, 1998
PubMed
Summary

Pravastatin effectively lowers cholesterol and triglycerides in diabetic patients with dyslipidemia. This lipid-lowering therapy showed no adverse effects on blood sugar control, proving safe for both type 1 and type 2 diabetes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining the unbound target exposure of teicoplanin, Part 2: Dose individualization through population pharmacokinetic modelling.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Follow-up of patients with urinary tract infections discharged from the emergency department: a mixed methods study.

The Journal of antimicrobial chemotherapy·2024
Same author

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy.

The Journal of antimicrobial chemotherapy·2020
Same author

Nationwide survey of hospital antibiotic stewardship programs in France.

Medecine et maladies infectieuses·2019
Same author

Management of infected pancreatic necrosis in the intensive care unit: a narrative review.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same author

Comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: A cross-sectional survey.

International journal of antimicrobial agents·2019

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus (DM), encompassing type 1 and type 2, significantly elevates the risk of coronary heart disease due to accelerated atherosclerosis.
  • Dyslipidemia is a common comorbidity in diabetic patients, contributing significantly to the progression of atherosclerosis and cardiovascular risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of pravastatin, a HMG-CoA reductase inhibitor, in managing hypercholesterolemia in patients with type 1 and type 2 diabetes.
  • To assess the impact of pravastatin on lipid profiles, including total cholesterol, LDL, HDL, and triglycerides, in this patient population.

Main Methods:

  • A randomized, placebo-controlled study involving 49 patients with type 1 (n=22) and type 2 (n=27) diabetes mellitus.
  • Patients received either pravastatin (20 mg/day) or a placebo for 24 weeks.

Related Experiment Videos

  • Lipid levels (TC, LDL, HDL, TG) and glycemic control were monitored throughout the study.

    • Main Results:

    • Pravastatin treatment resulted in significant reductions in total cholesterol (22.2%), LDL cholesterol (25.8%), and triglycerides (13.6%) after 24 weeks.
    • No significant changes were observed in high-density lipoprotein (HDL) cholesterol levels.
    • The lipid-lowering effects and safety profile of pravastatin were consistent across both type 1 and type 2 diabetic patients, with no deterioration in glycemic control.

    Conclusions:

    • Pravastatin is an effective and safe therapeutic option for treating dyslipidemia in patients with type 1 and type 2 diabetes mellitus.
    • The study supports the use of pravastatin in managing cardiovascular risk factors associated with dyslipidemia in diabetic populations.
    • Pravastatin demonstrates a favorable safety profile, without negatively impacting glycemic control in diabetic patients.